6Klotz L, Boceon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix a 12-month camparativer and omized open-label parallel- group phase nl study in patients with prostate cancer [ J]. BJU Int, 2008,102 ( 11 ) : 1531-1538.
7de Bono JS, Logothetis C J, Molina A, et al. Abiraterone and increased survival in wctastatic prostate cancer [ J ]. N Engl J Med, 2011,364 (21) :1995-2005.
9Agus DB, Stadler WM, Shevrin DH, et al. Safety, efficacy, and phar- macodynarnics of the investigational agent ortonel (TAK-700)in meta- static castration resistant prostate cancer (mCRPC):updated data from a phase 1 / II study[J]. J Clin Oncol,2012,30(5) :98.
10Shen HC, Balk SP. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer [ J ]. Cancer Ce11,2009,15(6) :461-463.
4VOGELZANG NJ,NELSON JB,SCHULMAN CC,et al.Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer[J].J Clin Oncol,2005,23(Suppl):4563.
5JAMES ND,CATY A,BORRE M,et al.Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic:a doubleblind,placebo-controlled,randomized,Phase Ⅱ trial[J].Eur Urol 2009,55:1112-1123.
6SCHER HI,HALABI S,TANNOCK IF,et al.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:Recommendations of the Prostate Cancer Clinical Trials Working Group[J].J Clin Oncol,2008,26:1148-59.
7TANNOCK IF,DEW IT R,BERRY WJ,et al.Docetaxel plus prednisone or mit oxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med,2004,351:1502-1512.
8BERTHOLD DR,POND GR,SOBAN F,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study[J].J Clin Oncol,2008,26:242-245.
9BEER TM,RYAN CW,VENNER PM,et al.Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer.Results from ASCENT,a double blinded,randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docctaxel[C].Paper presented at:American Society of Clinical Oncology Multi-disciplinary Prostate Cancer Symposium.2006.
10HAMBERG P,VERHAGEN PCMS,DE WIT R.When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?[J].Eur J Cancer,2008,44:1193-1197.
4Jochems C, Tucker JA, Tsang KY, et al. A combination trial of vac- cine plus ipilimumab in metastatic castration - resistant prostate cancer patients : immunecorrelates [ J ]. Cancer Immunol Immunoth- er, 2014,63(4) :407 -418.
5Guo W, Liu R, Bhardwaj G, et al. Targeting Btk/Etk of prostate cancer ceils by a novel dual inhibitor [ J ]. Cell Death Dis, 2014, 5 : e1409.
